<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02249065</url>
  </required_header>
  <id_info>
    <org_study_id>GLI.04.SPR.US 10305</org_study_id>
    <nct_id>NCT02249065</nct_id>
  </id_info>
  <brief_title>Mirvaso in Use Study</brief_title>
  <official_title>MIRVASO® In Use Study: Managing Rosacea Through Assessment and Control of Its Erythema (The MIRACLE Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma Laboratories, L.P.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma Laboratories, L.P.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to:

        1. assess the signs and symptoms of rosacea, including erythema, without treatment and
           during treatment with Mirvaso® gel

        2. further characterize lifestyle impact and patient satisfaction with Mirvaso® treatment

        3. gain a better understanding of the real-world use of Mirvaso® on the pattern and
           management of facial erythema of rosacea.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pre-Treatment Clinician Erythema Assessment (CEA)</measure>
    <time_frame>14 days (Day 1 (Baseline), Day 7, and Day 14/Exit)</time_frame>
    <description>The number and percent of subjects in each CEA score category at each visit. CEA was conducted at the screening/baseline visit and all subsequent visits prior to the study drug application.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subject Facial Redness Questionnaire</measure>
    <time_frame>14 days (Day 1 (Baseline) and Day 14/Exit)</time_frame>
    <description>Facial Redness Questionnaire at Day 1 and Day 14 (Mean Number of Subjects Who's Responses Indicate They Were/Were Not Bothered By Facial Redness, Across All 11 Facial Redness Questions)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Treatment Satisfaction Questionnaire</measure>
    <time_frame>14 days (Day 14/Exit)</time_frame>
    <description>Mean Subject Treatment Satisfaction at Day 14 (Average Response Across 12 Questions)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Facial Redness Visual Analog Scale (VAS)</measure>
    <time_frame>14 days (Day 1 (Baseline), Day 14/Exit)</time_frame>
    <description>The number and percent of subjects in each transformed response category for the in-office subject reported facial redness VAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Lesions</measure>
    <time_frame>14 days (Day 1 (Baseline) and Day 14/Exit)</time_frame>
    <description>Change from baseline in facial inflammatory lesion count</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">205</enrollment>
  <condition>Rosacea</condition>
  <arm_group>
    <arm_group_label>Mirvaso Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brimonidine topical gel, 0.33%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brimonidine</intervention_name>
    <arm_group_label>Mirvaso Gel</arm_group_label>
    <other_name>Mirvaso Gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must be 18 years of age or older at time of study consent.

          2. Subjects with a board certified dermatologist (BCD) clinical diagnosis of facial
             erythema of rosacea and eligible for treatment with Mirvaso® (brimonidine) topical
             gel, 0.33% per package insert.

          3. Subjects with a clinician's erythema assessment (CEA) score of ~3 at Screening Visit
             1.

          4. Subjects with less than 3 facial inflammatory lesions of rosacea at Screening/Visit 1.

          5. Subjects must be willing and able to give written informed consent including
             photography consent. Consent and photo consent will be obtained prior to any study
             related procedures

          6. Females of childbearing potential with a negative urine pregnancy test (UPT) at Visit
             1 (prior to test article application) or females of non-childbearing potential (deemed
             as post-menopausal [absence of menstrual bleeding for at least 1 year prior to
             enrollment], hysterectomy or bilateral oophorectomy).

        Exclusion Criteria:

          1. Subjects with particular forms of rosacea (rosacea conglobata, rosacea fulminans,
             isolated rhinophyma, isolated pustulosis of the chin) or other concomitant facial
             dermatoses that are similar to rosacea such as peri-oral dermatitis, demodicidosis,
             facial keratosis pilaris, seborrheic dermatitis, acute lupus erythematosus, or actinic
             telangiectasia.

          2. Subjects with current diagnosis of Raynaud's syndrome, thromboangiitis obliterans,
             orthostatic hypotension, severe cardiovascular disease, cerebral or coronary
             insufficiency, renal or hepatic impairment, scleroderma, Sjogren's syndrome or
             depression.

          3. Subjects with previous refractive eye surgery such as photorefractive keratectomy,
             laser-assisted sub-epithelial keratectomy, or laser-assisted in situ keratomileusis.

          4. Current treatment with monoamine oxidase inhibitors.

          5. Current treatment with barbiturates, opiates, sedatives, systemic anesthetics, or
             alpha- agonists.

          6. Less than 3 months (90 days) stable dose treatment with tricyclic antidepressants,
             cardiac glycosides, beta blockers or other antihypertensive agents.

          7. Subjects with any uncontrolled chronic or serious disease or medical condition that
             would normally prevent participation in a clinical study, or, in the judgment of the
             investigator, would put the subjects at undue risk, or might confound the study
             assessments (e.g., other dermatological diseases), or might interfere with the
             subjects' participation in the study, (e.g., planned hospitalization during the
             study).

          8. Subjects who have received, applied, or taken treatments with drugs, cosmetics or
             devices known to cause facial erythema and who are deemed ineligible by the
             investigator.

          9. Subjects with known allergies or sensitivities to any component of the study drug,
             including the active ingredient brimonidine tartrate label (refer to the package
             insert for Mirvaso® (brimonidine) topical gel, 0.33%).

         10. Subjects with prior treatment with brimonidine gel, oxymetazoline or other (topical
             and/or systemic) alpha adrenergic agonists.

         11. Subjects who are pregnant or breast-feeding or planning to become pregnant during the
             course of the study.

         12. Subjects exposed to excessive ultraviolet (UV) radiation within I week prior to
             baseline and/or subject was unwilling to refrain from excessive exposure to UV
             radiation during the course of the study.

         13. Subjects with the presence of a beard or excessive facial hair that would interfere
             with the study treatments or study assessments as deemed by the investigator, and
             refusal to remove beard or facial hair for duration of the study.

         14. Subjects with non-stable dose of current (last 60 days) use of prescription rosacea
             medications.

         15. Subjects with uncontrolled rosacea associated with inflammatory pustules and papules.

         16. Study site staff, relatives of staff members, or other individuals who would have
             access to the clinical study protocol.

         17. Subjects with participation in any investigational study within 30 days of entry into
             this study or concomitantly with this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Sugarman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Redwood Dermatology Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johnson Dermatology</name>
      <address>
        <city>Fort Smith</city>
        <state>Arkansas</state>
        <zip>72916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blue Harbor Dermatology</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Dermatology and Laser Surgery</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Redwood Dermatology Research</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Academic Dermatology Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of the Southeast</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grekin Skin Institute</name>
      <address>
        <city>Warren</city>
        <state>Michigan</state>
        <zip>48088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Skin Research Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manhattan Dermatology and Cosmetic Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermDox Centers for Dermatology</name>
      <address>
        <city>Hazleton</city>
        <state>Pennsylvania</state>
        <zip>18201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arlington Research Center</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Dermatology and Laser Specialists</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2014</study_first_submitted>
  <study_first_submitted_qc>September 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2014</study_first_posted>
  <results_first_submitted>September 19, 2017</results_first_submitted>
  <results_first_submitted_qc>September 19, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 19, 2017</results_first_posted>
  <last_update_submitted>November 21, 2017</last_update_submitted>
  <last_update_submitted_qc>November 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brimonidine Tartrate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mirvaso Gel</title>
          <description>Brimonidine Gel (topical emulsion (gel), 0.33% brimonidine, once daily)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="205"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="181"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="176"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>ITT Population, Subjects who received at least 1 application of study drug, and completed at least 1 assessment</population>
      <group_list>
        <group group_id="B1">
          <title>Mirvaso Gel</title>
          <description>Brimonidine Gel</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="181"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="143"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.4" lower_limit="22.0" upper_limit="85.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pre-Treatment Clinician Erythema Assessment (CEA)</title>
        <description>The number and percent of subjects in each CEA score category at each visit. CEA was conducted at the screening/baseline visit and all subsequent visits prior to the study drug application.</description>
        <time_frame>14 days (Day 1 (Baseline), Day 7, and Day 14/Exit)</time_frame>
        <population>Intent-to-treat (ITT) Population; Subjects who received at least 1 application of study drug, and completed at least 1 assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Mirvaso Gel</title>
            <description>Brimonidine Gel</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-Treatment Clinician Erythema Assessment (CEA)</title>
          <description>The number and percent of subjects in each CEA score category at each visit. CEA was conducted at the screening/baseline visit and all subsequent visits prior to the study drug application.</description>
          <population>Intent-to-treat (ITT) Population; Subjects who received at least 1 application of study drug, and completed at least 1 assessment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Baseline)</title>
              <category_list>
                <category>
                  <title>Clear Skin</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Almost Clear</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild Erythema</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate Erythema</title>
                  <measurement_list>
                    <measurement group_id="O1" value="144"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe Erythema</title>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <title>Clear Skin</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Almost Clear</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild Erythema</title>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate Erythema</title>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe Erythema</title>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <title>Clear Skin</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Almost Clear</title>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild Erythema</title>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate Erythema</title>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe Erythema</title>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Facial Redness Questionnaire</title>
        <description>Facial Redness Questionnaire at Day 1 and Day 14 (Mean Number of Subjects Who's Responses Indicate They Were/Were Not Bothered By Facial Redness, Across All 11 Facial Redness Questions)</description>
        <time_frame>14 days (Day 1 (Baseline) and Day 14/Exit)</time_frame>
        <population>ITT Population, Subjects who received at least 1 application of study drug, and completed at least 1 assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Mirvaso Gel</title>
            <description>Brimonidine Gel</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Facial Redness Questionnaire</title>
          <description>Facial Redness Questionnaire at Day 1 and Day 14 (Mean Number of Subjects Who's Responses Indicate They Were/Were Not Bothered By Facial Redness, Across All 11 Facial Redness Questions)</description>
          <population>ITT Population, Subjects who received at least 1 application of study drug, and completed at least 1 assessment</population>
          <units>Participants</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not Bothered (Mean [SD], Day 1, Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.3" spread="39.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bothered (Mean [SD], Day 1, Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.7" spread="40.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing (Day 1, Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Bothered (Mean [SD], Day 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.6" spread="28.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bothered (Mean [SD], Day 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.3" spread="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing (Day 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread=".3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Treatment Satisfaction Questionnaire</title>
        <description>Mean Subject Treatment Satisfaction at Day 14 (Average Response Across 12 Questions)</description>
        <time_frame>14 days (Day 14/Exit)</time_frame>
        <population>ITT Population, Subjects who received at least 1 application of study drug, and completed at least 1 assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Mirvaso Gel</title>
            <description>Brimonidine Gel</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Treatment Satisfaction Questionnaire</title>
          <description>Mean Subject Treatment Satisfaction at Day 14 (Average Response Across 12 Questions)</description>
          <population>ITT Population, Subjects who received at least 1 application of study drug, and completed at least 1 assessment</population>
          <units>Participants</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Satisfied Participants (Mean [SD])</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.3" spread="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dissatisfied Participants (Mean [SD])</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.7" spread="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Facial Redness Visual Analog Scale (VAS)</title>
        <description>The number and percent of subjects in each transformed response category for the in-office subject reported facial redness VAS</description>
        <time_frame>14 days (Day 1 (Baseline), Day 14/Exit)</time_frame>
        <population>ITT Population, Subjects who received at least 1 application of study drug, and completed at least 1 assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Mirvaso Gel</title>
            <description>Brimonidine Gel</description>
          </group>
        </group_list>
        <measure>
          <title>Facial Redness Visual Analog Scale (VAS)</title>
          <description>The number and percent of subjects in each transformed response category for the in-office subject reported facial redness VAS</description>
          <population>ITT Population, Subjects who received at least 1 application of study drug, and completed at least 1 assessment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Very Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Very Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Very Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Very Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inflammatory Lesions</title>
        <description>Change from baseline in facial inflammatory lesion count</description>
        <time_frame>14 days (Day 1 (Baseline) and Day 14/Exit)</time_frame>
        <population>ITT Population, Subjects who received at least 1 application of study drug, and completed at least 1 assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Mirvaso Gel</title>
            <description>Brimonidine Gel</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammatory Lesions</title>
          <description>Change from baseline in facial inflammatory lesion count</description>
          <population>ITT Population, Subjects who received at least 1 application of study drug, and completed at least 1 assessment</population>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1: Lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".6" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14: Lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14: Change From Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>29 Days</time_frame>
      <desc>Adverse events were recorded for at least 14 days prior to the first treatment application.</desc>
      <group_list>
        <group group_id="E1">
          <title>Mirvaso Gel</title>
          <description>Brimonidine Gel</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA version 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>condition aggravated</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rosacea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Open label, single arm, short duration.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Jean Philippe York</name_or_title>
      <organization>Galderma Laboratories L.P.</organization>
      <phone>817-961-5468</phone>
      <email>jp.york@galderma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

